Core Viewpoint - IceCure Medical Ltd. has completed its rights offering, allowing shareholders to purchase up to 10,000,000 units at a subscription price of $1.00 per unit, generating approximately $10 million in gross proceeds [1][5]. Rights Offering Details - The subscription period for the rights offering expired on July 28, 2025, at 5:00 p.m. Eastern Time [1]. - Each holder of ordinary shares received one subscription right for every share owned, allowing them to subscribe for 0.1703 of a unit, which includes one ordinary share and a warrant [2]. - Holders who fully exercised their basic subscription rights could subscribe for additional units that remained unsubscribed [3]. Subscription Results - A total of 10,000,000 units were validly subscribed during the rights offering, with 4,627,771 units expected to be issued under the over-subscription privilege [4]. - The company plans to deliver the ordinary shares and warrants to rights holders on or about July 30, 2025 [4]. Financial Implications - The estimated gross proceeds from the rights offering are approximately $10 million, excluding related expenses [5]. Company Overview - IceCure Medical develops minimally-invasive cryoablation technology for tumor destruction, focusing on breast, kidney, bone, and lung cancers [10].

Core Viewpoint - IceCure Medical Ltd. is conducting a Rights Offering that allows existing shareholders to purchase units at a subscription price of $1.00 per unit, with the subscription period expiring on July 28, 2025 [1][6]. Group 1: Rights Offering Details - The Company distributed non-transferable subscription rights to holders of its ordinary shares as of July 9, 2025, allowing them to purchase up to 10,000,000 units at a price of $1.00 per unit [2]. - Each holder of the Company's ordinary shares will receive one subscription right for every share owned, with each subscription right entitling the holder to purchase 0.1703 of a unit, which includes one ordinary share and a warrant [6]. - The Rights Offering is being managed by Maxim Group LLC, and all inquiries regarding the offering can be directed to them [7]. Group 2: Subscription Process - Rights holders must contact their brokers or nominees to exercise their subscription rights and submit payment by the deadline, which may be set earlier than July 28, 2025 [3]. - The subscription rights will expire if not exercised by the specified deadline, and no fractional subscription rights or units will be issued [6]. Group 3: Company Overview - IceCure Medical develops and markets advanced cryoablation therapy systems for tumor destruction, focusing on breast, kidney, bone, and lung cancers [12]. - The Company's flagship product, the ProSense® system, is marketed globally and offers a minimally invasive alternative to surgical tumor removal [12].

Core Points - Atico Mining Corporation successfully closed its rights offering, raising gross proceeds of $3,287,572.42 by issuing 29,887,022 units at a subscription price of $0.11 per unit [1][3] - Each unit consists of one common share and one transferable common share purchase warrant, which can be exercised at $0.18 per share for two years [2] - Approximately 41% of the total rights units were issued to insiders, with the remaining rights expiring unexercised [3] Financial Details - The rights offering resulted in the issuance of 11,219,319 units through the basic subscription privilege and 18,667,703 units through the additional subscription privilege [3] - Following the offering, the total number of common shares outstanding is 151,173,207 [3] Future Plans - The company plans to utilize the net proceeds from the rights offering and an upcoming LIFE offering for the development of the La Plata project in Ecuador, additional drilling at the El Roble mine in Colombia, and general corporate purposes [5][4]

Core Viewpoint - NXG NextGen Infrastructure Income Fund's Board has approved the issuance of transferable rights to existing common shareholders, allowing them to subscribe for additional common shares at a discount to market price, aimed at increasing the Fund's investment assets and taking advantage of future investment opportunities [1][2][12]. Group 1: Offer Details - The record date for the rights issuance is set for July 21, 2025, with one right distributed for each common share held [2]. - Shareholders can purchase one new common share for every three rights held, with a provision for those holding fewer than three shares [2]. - The subscription period will start on the record date and is expected to end on August 13, 2025, unless extended [3]. Group 2: Subscription Price - The subscription price will be determined on the expiration date, set at 95% of the average sales price of the common shares on that day and the preceding four trading days, with a minimum price of 90% of the Fund's net asset value if the formula price is lower [4]. Group 3: Over-Subscription Privilege - Record date common shareholders who fully exercise their primary subscription rights will have the opportunity to subscribe for additional common shares not purchased in the primary subscription, subject to limitations [5]. Group 4: Distribution Information - The Fund has declared a monthly distribution of $0.54 per common share, payable on August 29, 2025, with a record date change to August 4, 2025 [7][8]. - The distribution is anticipated to be treated as a return of capital, with an estimate of 100% based on current earnings and profits [8]. Group 5: Fund Overview - NXG NextGen Infrastructure Income Fund is a closed-end management investment company focused on achieving high total returns with an emphasis on current income, primarily investing in infrastructure-related equity and debt securities [12]. - The Fund aims to invest at least 80% of its net assets in various infrastructure sectors, including energy, industrial, sustainable, and technology infrastructure [12].

Core Viewpoint - IceCure Medical Ltd. has initiated a rights offering to raise funds through the sale of subscription rights to existing shareholders, aiming to generate up to $10 million in gross proceeds [1][4]. Rights Offering Details - The rights offering allows holders of the Company's ordinary shares as of July 9, 2025, to purchase up to 10,000,000 units at a subscription price of $1.00 per unit [2][4]. - Each ordinary share owned on the record date grants one subscription right, allowing the purchase of 0.1703 of a unit, which includes one ordinary share and a warrant [3][4]. - The subscription rights will expire on July 28, 2025, unless extended by the Company, and no fractional subscription rights or units will be issued [3][5]. Financial Implications - If fully subscribed, the rights offering is expected to yield gross proceeds of $10 million, which will be used to repay a $2 million bridge loan from Epoch Partner Investments Limited and for general corporate purposes [4][10]. - Epoch, the largest shareholder, has committed to fully participate in the rights offering, potentially subscribing for up to $5 million [4]. Management and Regulatory Aspects - Maxim Group LLC has been appointed as the dealer-manager for the rights offering, and the offering is being conducted under a registration statement declared effective by the SEC [6][7]. - The rights offering is made only by means of a prospectus, which will be provided to eligible shareholders [7]. Company Overview - IceCure Medical specializes in minimally invasive cryoablation technology for tumor destruction, focusing on various cancers including breast, kidney, bone, and lung cancer [10].

Core Viewpoint - IceCure Medical Ltd. has announced a rights offering to raise up to $10 million, allowing existing shareholders to purchase additional units at specified prices, with the aim of repaying a bridge loan and for general corporate purposes [1][2]. Group 1: Rights Offering Details - The rights offering will provide each shareholder with one subscription right for each ordinary share held as of July 9, 2025, allowing them to subscribe for 0.1703 of a unit at a price of $1.00 per unit or a pre-funded warrant at $0.9999 per unit [1][2]. - The subscription rights will expire on July 28, 2025, at 5:00 p.m. Eastern Time, and shareholders must exercise their rights for at least one whole unit to participate [1][6]. - If fully subscribed, the company expects to receive gross proceeds of $10 million, with Epoch Partner Investments Limited committed to participate with up to $5 million [2]. Group 2: Financial Context - The proceeds from the rights offering will be used to repay a $2 million unsecured bridge loan from Epoch, which carries an interest rate of 4.05% and is due after 12 months or upon completion of the rights offering [2]. - Epoch's director is also a member of IceCure's board, indicating a close relationship between the two entities [2]. Group 3: Company Overview - IceCure Medical specializes in minimally invasive cryoablation technology for tumor destruction, focusing on various cancers including breast, kidney, bone, and lung [8]. - The company's flagship product, the ProSense® system, is marketed globally and offers a safe alternative to surgical tumor removal [8].

Core Viewpoint - Prime Drink Group Corp. is initiating a rights offering to raise a minimum of $3 million, aimed at recapitalizing the company and facilitating the acquisition of Triani Canada Inc. from receivership [1][2][4]. Group 1: Rights Offering Details - The company will offer a maximum of 353,409,888 rights to existing shareholders, with each right allowing the purchase of one share at a price of $0.0825 [1][3]. - The rights offering is expected to result in a total of 706,819,776 shares outstanding if all rights are exercised, with the new shares representing 50% of the total [3]. - The rights will expire on July 25, 2025, at 4:00 p.m. Eastern time, after which unexercised rights will be void [5]. Group 2: Use of Proceeds - Proceeds from the rights offering are intended for re-acquiring Triani and for general working capital, corporate purposes, and administrative expenses [10]. - The company aims to participate in the process of re-acquiring Triani, which is currently in receivership due to creditor actions [4]. Group 3: Shareholder Participation - The rights will only be offered to shareholders residing in Canada, and registered shareholders must submit their subscription forms to the rights agent by the expiry time [6][7]. - Directors and senior officers of the company are expected to exercise a portion of their rights, although the exact number cannot be determined at this time [10].

Core Viewpoint - Atico Mining Corporation is conducting a Rights Offering and a LIFE Offering to raise a total of approximately $8,536,592 to support its operations and financial commitments [3][4]. Group 1: Offerings Details - The Rights Offering aims to raise gross proceeds of up to approximately $5,336,592, while the LIFE Offering is expected to generate up to approximately $3,200,000 [3]. - The amended Offering Documents include a term sheet with Trafigura PTE. Ltd. regarding an amendment and extension of the existing secured credit agreement [2][3]. - The Offering Documents will be available on SEDAR+ and the company's website for prospective investors [4]. Group 2: Company Overview - Atico Mining Corporation focuses on exploring, developing, and mining copper and gold projects in Latin America, generating significant cash flow from the El Roble mine and developing the La Plata VMS project in Ecuador [6].

Core Viewpoint - Atico Mining Corporation is conducting a rights offering and a concurrent LIFE offering to raise a total of approximately $8,536,592 for development projects and general corporate purposes [1][10][16]. Rights Offering - The rights offering will issue 48,514,474 rights to shareholders, allowing them to subscribe for units at a price of $0.11 per unit [2][3]. - Each unit consists of one common share and one transferable purchase warrant, exercisable at $0.18 for two years [3][11]. - The rights will expire on July 21, 2025, and unexercised rights will be void [5]. LIFE Offering - The LIFE offering aims to raise up to $3,200,000 by issuing 29,090,910 units at the same price of $0.11 per unit [10][12]. - Each LIFE unit also consists of one common share and one transferable purchase warrant, with similar terms as the rights offering [11]. Loan Refinancing - The company has a credit agreement with Trafigura for a principal sum of $10 million, with $8.7 million due by June 30, 2025 [15]. - Ongoing discussions are taking place for potential refinancing options [15]. Use of Proceeds - The net proceeds from the offerings will be allocated to the La Plata project in Ecuador, additional drilling at the El Roble mine in Colombia, and general corporate purposes [16]. Additional Information - The offerings may involve related parties and will be exempt from certain formal requirements under MI 61-101 [17]. - Detailed information regarding the offerings will be available in the company's offering documents on SEDAR+ [19].

Group 1 - The Cornerstone Total Return Fund, Inc. completed a one-for-three rights offering, allowing stockholders to purchase one new share for every three rights held, with a subscription price set at $6.97 [1][3] - The Fund received requests for approximately $207 million in shares, indicating strong demand, and anticipates issuing over-subscription shares under the additional subscription privilege [2] - The subscription price of $6.97 is higher than the initially estimated price of $6.29, and shares are expected to be issued around May 22, 2025 [3] Group 2 - Cornerstone Total Return Fund, Inc. is a closed-end, diversified management investment company registered with the SEC under the Investment Company Act of 1940 [4] - The Fund is traded on the NYSE American under the symbol "CRF" and is advised by Cornerstone Advisors, LLC, which also advises another closed-end fund, Cornerstone Strategic Investment Fund, Inc. [5]